myChoice HRD is a tumor test that can help guide important PARP inhibitor therapy decisions

myChoice HRD identifies patients that are most likely to benefit from PARP inhibitors. Every patient’s cancer is unique, so their treatment should be as well. Myriad’s myChoice HRD helps physicians select the most effective treatment for their patients, minimizing the time and toxicity associated with ineffective therapies.
Learn MoreIdentify More Hope
myChoice HRD’s unique phenotypic approach identifies more patients who are more likely to preferentially benefit from PARP inhibitors than BRCA testing alone.
Our brief and easy-to-use hereditary cancer quiz can help you determine whether you may be a candidate to get tested for several of the most common hereditary cancer syndromes.
Get StartedYou and your healthcare provider can determine your cancer risk and course of management by understanding your family history and pursuing hereditary cancer testing when appropriate.
Get Be Ready PackThe Family History Tool starts your pedigree chart with you adding information about yourself, then you’ll be asked for information about family members to complete your health history profile.
Get StartedTake this hereditary cancer survivor snapshot to learn if your cancer diagnosis might have been related to an inherited gene mutation. On average, the quiz takes less than 1 minute to complete.
Get Started